$48.21
$-1.57 (-3.15%)
End-of-day quote: 04/24/2024
NasdaqGM:JANX
Janux Therapeutics Annual Report
Year | Year | 2023 | 2022 | 2021 | ||
---|---|---|---|---|---|---|
Rev. | Revenue |
|
$8.08M | $8.61M | $3.64M | |
GM % | Gross Margin % |
|
2.60% | 0.00% | 0.00% | |
OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | |
EPS | Earnings Per Share |
|
$0.00 | $-1.32 | $-1.52 | $-1.39 |
Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | |
PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | |
Sha. | Shares |
|
46.24m | 41.62m | 41.24m | |
OCF | Operating Cash Flow |
|
$-50.58M | $-42.92M | $-16.98M | |
FCF | Free Cash Flow |
|
$-87.00M | $-67.09M | $-18.46M | |
FCFS | Free Cash Flow Per Share |
|
$-1.19 | $-1.19 | $-0.78 |